Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Total Liabilities
Everything the company owes to creditors and other parties.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 50.8% from a year ago
Total liabilities stood at $33.88M at the end of Q3 FY2026, up 50.8% from a year earlier and up 36.3% from the prior quarter. Over 3 fiscal years it compounded at +127.8% a year.
Context
- Total liabilities amounted to 2.8% of total assets at the end of Q3 FY2026, down 1.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +50.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.69M USD
- Year-over-year change
- +20.9%
- 4-year CAGR
- +44.0%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.69M | +20.9% |
| FY2024 | 2024-12-31 | 13.8M | +1540.7% |
| FY2023 | 2023-12-31 | 841K | -40.4% |
| FY2022 | 2022-12-31 | 1.41M | -63.6% |
| FY2021 | 2021-12-31 | 3.88M | — |
Total Liabilities vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's Sep 2026 total liabilities of $33.88M is the 7th highest of the 10 companies compared; the peer median is $55.07M.
- Its year-over-year change of +50.8% is the 3rd highest of 9, against a peer median of -5.9%.
- Total liabilities amounts to 2.8% of total assets for ORKA, versus a peer median of 25.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $316.94M | -18.3% | -2.1% | 96.1% | |
| Jun 2026 | $221.73M | -14.4% | +26.4% | 30.6% | |
| Mar 2026 | $146.35M | +48.3% | +145.8% | 36.6% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $108.46M | -13.6% | -28.6% | 19.3% |
| Mar 2026 | $55.07M | +1.9% | +0.2% | 27.7% | |
| Jun 2026 | $41.25M | +79.4% | +58.3% | 3.4% | |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $33.88M | +50.8% | +127.8% | 2.8% |
| Jun 2026 | $15.58M | — | — | 12.1% | |
| Dec 2025 | $14.1M | +54.6% | -5.2% | 25.1% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -23.1% | 5.1% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $55.07M | -5.9% | -0.9% | 25.1% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 53.36M | 42.45M | 37.43M | 61.58M | 46.94M |
| Short-term Investments | 0 | 0 | 0 | 314.07M | 290.11M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.06M | 254K | 161K | 1.22M | 6.81M |
| Total Current Assets | 54.42M | 42.7M | 37.59M | 376.87M | 343.86M |
| Property, Plant & Equipment (Net) | 485K | 368K | 257K | 1.04M | 2.12M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 18.07M | 142.54M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 18K | 18K | 12K | 43K | 103K |
| Total Non-current Assets | 503K | 386K | 269K | 19.15M | 144.76M |
| Total Assets | 54.92M | 43.09M | 37.86M | 396.02M | 488.62M |
| Account Payables | 1.12M | 334K | 0 | 3.46M | 4.16M |
| Short-term Debt | 100K | 103K | 76K | 213K | 619K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.36M | 522K | 461K | 7.33M | 5.33M |
| Total Current Liabilities | 3.5M | 1.13M | 637K | 13.04M | 15.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 383K | 280K | 204K | 755K | 1.31M |
| Total Liabilities | 3.88M | 1.41M | 841K | 13.8M | 16.69M |
| Common Stock | 14K | 14K | 14K | 37K | 49K |
| Retained Earnings | (173.48M) | (183.4M) | (188.74M) | (83.72M) | (189.16M) |
| Accumulated OCI | 0 | 0 | 0 | (41K) | 546K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 51.04M | 41.67M | 37.02M | 382.22M | 471.93M |
| Total Debt | 483K | 383K | 280K | 968K | 1.93M |
| Net Debt | (52.88M) | (42.06M) | (37.15M) | (60.61M) | (45M) |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.